
|Videos|February 27, 2019
Dr. Budde Highlights Unique Aspects of Mosunetuzumab Trial in Follicular Lymphoma
Author(s)Elizabeth Lihua Budde, MD, PhD
Elizabeth Lihua Budde, MD, PhD, discusses how the phase I/Ib clinical trial for mosunetuzumab in patients with follicular lymphoma is different than other clinical trials.
Advertisement
Elizabeth Lihua Budde, MD, PhD, an assistant professor at City of Hope, discusses how a phase I/Ib clinical trial evaluating mosunetuzumab in patients with follicular lymphoma (FL) is different than other clinical trials.
Patients receive this novel treatment for a limited number of cycles, Budde says. Initial treatment is only 8 cycles, and the patient may remain in follow-up rather than being treated until progression or relapse.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































